The Wakefit Innovations IPO is a closed mainboard Bookbuilding offer (Fresh Capital-cum-Offer for Sale) that opened on 8 December 2025. The Wakefit Innovations IPO closed on 10 December 2025, with an issue price of ₹195 per share. The Wakefit Innovations IPO has a face value of ₹1 and a lot size of 76 shares. The Wakefit Innovations IPO is listed on 15 December 2025. The Wakefit Innovations IPO allotment was scheduled for 11 December 2025.
On the financial front, the Wakefit Innovations IPO reported revenue of ₹741 crore for 30 Sep 2025, compared with ₹1,305 crore for 31 Mar 2025. The Wakefit Innovations IPO PAT was ₹36 crore against ₹-35 crore. The Wakefit Innovations IPO EBITDA stood at ₹103 crore with a 7.13% margin. The Wakefit Innovations IPO net worth as of 30 Sep 2025 was ₹557 crore.
Always verify The Wakefit Innovations IPO details and GMP data with the official offer document before investing in the Wakefit Innovations IPO.
Financial Summary
Amount in ₹ Crore
Metric
30 Sep 2025
31 Mar 2025
31 Mar 2024
Total Assets
1,220
1,051
928
Revenue
741
1,305
1,017
PAT
36
-35
-15
EBITDA
103
91
66
Net Worth
557
521
544
Reserves
522
500
523
Total Borrowing
—
—
7
Wakefit Innovations IPO Financials FAQs
Revenue of Wakefit Innovations (Amount in ₹ Crore) — 30 Sep 2025: 741; 31 Mar 2025: 1,305; 31 Mar 2024: 1,017. Profit after tax (PAT) — 30 Sep 2025: 36; 31 Mar 2025: -35; 31 Mar 2024: -15.
EBITDA of Wakefit Innovations (Amount in ₹ Crore) — 30 Sep 2025: 103; 31 Mar 2025: 91; 31 Mar 2024: 66. The EBITDA margin is 7.13%.
Total assets — 30 Sep 2025: 1,220; 31 Mar 2025: 1,051; 31 Mar 2024: 928. Net worth — 30 Sep 2025: 557; 31 Mar 2025: 521; 31 Mar 2024: 544. Reserves & surplus — 30 Sep 2025: 522; 31 Mar 2025: 500; 31 Mar 2024: 523. (Amount in ₹ Crore)
Total borrowing of Wakefit Innovations (Amount in ₹ Crore) — 31 Mar 2024: 7. Debt-to-equity ratio: 0.53.
The financials shown for Wakefit Innovations IPO are taken from the company's offer document (DRHP/RHP/prospectus) filed with the exchange and SEBI, and are updated here when restated figures are published. Always cross-check with the official offer document before investing.
Look at the trend of revenue and PAT across periods, whether EBITDA is growing along with revenue, and whether net worth is rising while borrowings stay under control. The first column may be a part-year (interim) period, so compare full financial years with each other.
GMP and IPO data are unofficial and for information only — not investment advice.
Read the full disclaimer.
